Cami

ADC Therapeutics sells off royalty share for lead antibody-drug conjugate in $325M deal
Endpoints
Thu, 08/26/21 - 10:53 am
ADC Therapeutics
Zynlonta
Cami
camidanlumab tesirine
FDA lifts partial hold on ADC, clearing way for a 2021 readout and two potential near-term approvals
Endpoints
Mon, 07/6/20 - 11:01 am
ADC Therapeutics
IPOs
FDA
Cami
Hodgkin's lymphoma